Thomas Huenig
Direktor/Vorstandsmitglied bei TeGenero AG
Aktive Positionen von Thomas Huenig
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TeGenero AG
TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Direktor/Vorstandsmitglied | 01.06.2000 | - |
Karriereverlauf von Thomas Huenig
Ausbildung von Thomas Huenig
Wuerzburg Schweinfurt University of Applied Sciences | Doctorate Degree |
Statistik
International
Deutschland | 3 |
Operativ
Director/Board Member | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
TeGenero AG
TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Health Technology |
- Börse
- Insiders
- Thomas Huenig
- Erfahrung